EXPERIENCE OF USING OF OCTREOTIDE-DEPOT IN PREVENTION OF THE DEVELOPMENT AND TREATMENT OF EXTERNAL PANCREATIC FISTULAS OF DIFFERENT GENESIS
https://doi.org/10.24884/0042-4625-2013-172-3-094-096
Abstract
In the period from 2011 till 2012 the Otcreotide-depot was used by the authors in treatment of 34 patients. The patients were divided into two groups: the first group — the prevention of development and the second group — the treatment of external pancreatic fistulas. Ocreotide-depot was applied in 17 patient of the first group: as part of the complex therapy of severe pancreatitis in 4 patients and after pacreaticoduodenectomy in 13 patients. Ocreotide-depot was used in 17 patients of the second group: 7 cases of patients after different types of pancreatic resections and after external drainage of pancreatic cysts in 10 patients. The positive effect of using the drug was obtained in 30 patients (88,25%): the cases of preventive application of drug in 17 patients and during the treatment of external pancreatic fistulas in 13 patients. The preventive and therapeutic usage of Ocreotide-depot facilitated an uncomplicated postoperative period in 13 cases and the healing of the external pancreatic fistulas in terms from 5 till 7 days in 13 patients. The application of Ocreotide-depot could be recommended as a preventive measure against the incompetence of pancreaticojejunoanastomosis after pancreaticoduodenectomy in complex therapy of severe pancreatitis and also in treatment of external pancreatic fistulas after pancreaticoduodenectomy and percutaneous drainage of postnecrotic pseudocysts.
About the Authors
M. Yu. Kabanov
Kirov Military Medical Academy
Russian Federation
Russian Federation
I. A. Soloviev
Kirov Military Medical Academy
Russian Federation
Russian Federation
D. M. Yakovleva
Djanelidze Research Institute of Emergency Medicine
Russian Federation
Russian Federation
K. V. Sementsov
Kirov Military Medical Academy
Russian Federation
Russian Federation
A. V. Kradenov
Djanelidze Research Institute of Emergency Medicine
Russian Federation
Russian Federation
References
1. Афанасьев С. Г., Авдеев С. В., Августинович А. В., Пак А. В. Возможности медикаментозной профилактики послеоперационного панкреатита при хирургическом лечении рака желудка // Сибирский онкол. журн. 2011. № 5. C. 24–28.
2. Багненко С. Ф., Курыгин А. А., Рухляда Н. В., Смирнов А. Д. Хронический панкреатит. СПб.: Питер, 2000. С. 31–38.
3. Белоконев В. И., Катасонов М. В., Качанов В. А. и др. Свищи желудочно-кишечного тракта при панкреонекрозе // Хирургия. 2009. № 3. С. 61–64.
4. Бобров О. Е., Мендель Н. А. Мифы панкреатологии: соматостатин и октреотид при остром панкреатите // Украинск. журн. хир. 2007. № 1. С. 85–92.
5. Крылов Н. Н., Егоров А. В., Латифова Л. В., Вычужанин Д. В. Клинико-экономические аспекты медикаментозной профилактики острого послеоперационного панкреатита // Вестн. хир. гастроэнтерологии. 2011. № 1. C. 10–16.
6. Черноусов А. Ф., Егоров А. В., Черноусов Ф. А. и др. «Октреотид-депо» в профилактике панкреатита после радикальных операций при раке желудка с расширенной лимфаденэктомией // Хирургия. 2012. № 8. C. 44–50.
7. Ярошенко В. Г., Михеев В. Г., Криворучко И. В. Применение Соматулина в лечении осложнений после операций на поджелудочной железе // Клiн. хiр. 2009. № 1. С. 23–25.
8. Abdullah A. Alghamdi, Ali M. Jawas, Richard S. Hart. Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis // Can. J. Surg. 2007. Vol. 50, № 6. P. 459–466.
9. Baillie J. Management of pancreatic fistula? // Medscape Gastroenterology. 2005. Vol. 7, № 1.
10. Berberat P. O., Friess H., Uhl W., Buchler M. W. The role of octreotide in prevention of complication following pancreatic resection // Digestion. 1999. Vol. 60, № 2. P. 15–22.
11. Gouillat C., Gigot J.-F. Pancreatic surgical complications — the case for profilaxis // Gut. 2001. Vol. 49: iv29–iv35 doi:10.1136/ gut.49.suppl_4.iv29.
12. Li J., Ren J., Zhu W. et al. Management of enterocutaneos fistulas: 30-year clinical experience // Chin. Med. J. 2003. Vol. 116, № 2. P. 171–175.
13. Li-Ling J., Irving M. Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized, controlled trials // Br. J. Surg. 2001. Vol. 882. P. 190–199.
14. Matheus A. S., Montagnini A. L., Jukemura J. et al. Does Octreotide has any beneficial effect in patients with high risk to develop pancreatic fistula after pancreaticoduodenectomy: a prospective randomized trial / The society for surgery of the alimentary tract. Materials of 50th Annual Meeting // Gastroenterology. 2009. Vol. 136: iv5. suppl. 1. P. A881.
15. The Department of Surgical Education, Orlando Regional Medical Center. Octreotide in the prevention and treatment of gastrointestinal and pancreatic fistulas. Revised 06.10.2009. P. 1–8.
16. Tulassay Z., Flautner L., Vadasz A., Fehervari I. Shot report: octreotide in the treatment of external pancreatic fistulas // Alimentary Pharmacology & Therapeutics. 1993. Vol. 7, № 3. P. 323–325.
17. Vanounou T., Pratt W. B., Callery M. P., Vollmer C. M. Jr. Selective administration of prophylactic octreotide during pancreaticoduodenectomy: a clinical and cost-benefit analysis in low- and high — risk glands // J. Am. Coll. Surg. 2007. Vol. 4. P. 546–557.
18. Xeropotamos N., Nastos D., Nousias V. et al. Octreotide plus total parenteral nutrition in patients with external digestive tract fistulas — an evaluation of our experience // Ann of Gastroenterology. 2005. Vol. 18. № 4. P. 427–433.
Review
For citations:
Kabanov M.Yu., Soloviev I.A., Yakovleva D.M., Sementsov K.V., Kradenov A.V. EXPERIENCE OF USING OF OCTREOTIDE-DEPOT IN PREVENTION OF THE DEVELOPMENT AND TREATMENT OF EXTERNAL PANCREATIC FISTULAS OF DIFFERENT GENESIS. Grekov's Bulletin of Surgery. 2013;172(3):094-096. (In Russ.) https://doi.org/10.24884/0042-4625-2013-172-3-094-096
Views:
433
Email this article 